PDCD1 and inflammatory bowel disease: Recombinant Fc-conjugated PD-L1 is a promising biologic for achieving anti-inflammatory effects with IBD therapy due to the suppression of immune cells and their cytokine production via interactions with PD-1 and B7-117.